Fred Hutch: Monoclonal Antibody Treatment Highly Effective at Reducing COVID-19 Hospitalizations
October 28, 2021
October 28, 2021
SEATTLE, Washington, Oct. 28 (TNSJou) -- The Fred Hutchinson Cancer Research Center issued the following news release on Oct. 27, 2021:
Researchers today published interim results in The New England Journal of Medicine from a Phase 3 study of the COVID-19 monoclonal antibody treatment sotrovimab, sponsored by Vir Biotechnology and GlaxoSmithKline. The study found that compared to the placebo group, COVID-19 patients who received sotrovimab had a significantly reduced risk of hospita . . .
Researchers today published interim results in The New England Journal of Medicine from a Phase 3 study of the COVID-19 monoclonal antibody treatment sotrovimab, sponsored by Vir Biotechnology and GlaxoSmithKline. The study found that compared to the placebo group, COVID-19 patients who received sotrovimab had a significantly reduced risk of hospita . . .